Ziepert, Marita <br/><br/>
Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  May 2010 
 - 2373-80 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2009.26.2493  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antigens, CD20--immunology<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Computer Simulation<br/>Cyclophosphamide--administration & dosage<br/>Disease Progression<br/>Disease-Free Survival<br/>Doxorubicin--administration & dosage<br/>Female<br/>Health Status Indicators<br/>Humans<br/>Kaplan-Meier Estimate<br/>Lymphoma, B-Cell--diagnosis<br/>Male<br/>Middle Aged<br/>Predictive Value of Tests<br/>Prednisone--administration & dosage<br/>Proportional Hazards Models<br/>Prospective Studies<br/>Risk Assessment<br/>Risk Factors<br/>Rituximab<br/>Time Factors<br/>Treatment Outcome<br/>Vincristine--administration & dosage<br/>Young Adult